



IMMUNE EVENTS FOLLOWING IMMUNOABLATIVE THERAPY FOR THE
TREATMENT OF MULTIPLE SCLEROSIS (MS)
Atkins, H.1, Freedman, M.1, Bowman, M.1, Bar-Or, A.2, Cheynier,
R.2, Corsini, R.2, Jalili, F.3, Kim, H.J.3, Miller, L.3, Sekaly, R.3,
Canadian MSBMT Study Group. 1. The Ottawa Hospital, Ottawa, ON,
Canada; 2. Montreal Neurological Institute of McGill University, Mon-
treal, QC, Canada; 3. University of Montreal, Montreal, QC, Canada
This report details the immunology of the ﬁrst patient enrolled
in the Canadian trial of immunoablative therapy with autologous
stem cell transplantation (SCT) for MS. This trial tests the concept
that immunoablative therapy can stop autoimmunity in MS and
halt further CNS damage. Furthermore reconstitution of a naïve
immune system should be functional and self-tolerant. A 31-year-
old woman with secondary progressive MS underwent a CD34
selected autologous SCT after receiving Busulphan (16 mg/kg),
Cyclophosphamide (200 mg/kg) and rabbit ATG (5 mg/kg). MS
Activity: The patient is clinically stable 24 mo. post SCT with no
relapses or progression of disabilities. There is sustained resolution
of gadolinium activity and improved T2 metrics by MRI. Thus MS
activity has been shut down. Immune ablation: The patient be-
came lymphopenic. All lymphocyte subpopulations were de-
creased. There was loss of humoral immunity to mumps and
measles at 18 mo. post SCT and lost cutaneous reactivity to
candida at 6 and 12 mo. post SCT. Antigen speciﬁc in vitro T cell
responses to myelin basic protein (MBP), tetanus toxoid (TT) and
copaxone (GA) were reduced or abolished following SCT. There
was 1000 fold reduction in recent thymic emigrants 3 mo. post
SCT and a reduction in circulating naı¨ve T cells. Thus immuno-
ablation was achieved. Immune reconstitution: The patient has
not developed opportunistic infections. The lymphocyte count has
slowly risen during the post SCT period. Both helper and suppres-
sor populations remain profoundly low with mainly a memory
phenotype. The CD4:CD8 ratio normalized at 12 mo. post SCT.
Thymic emigrants in the circulation have increased to about 10%
of baseline. B cell and immunoglobulin levels are normal. Humoral
immunity is polyclonal. A positive cutaneous response to candida
antigen testing occurred 24 mo. post SCT. Speciﬁc in vitro T cell
responses to TT following reimmunization are currently being
evaluated. This preliminary data suggests that the post transplant
immune system is protective and self-tolerant. The data from this
patient indicates that complete immunoablation was achieved and
is associated with a signiﬁcant change in MS activity. The patient
remains lymphopenic but is not prone to opportunistic infections.
Immune reconstitution is ongoing and is NOT associated with
recurrence of MS activity.
162
AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR TAKA-
YASU’S ARTERITIS: REPORT OF THE FIRST CASE OF THE LITERATURE
Voltarelli, J.C., Oliveira, M.-C.B., Stracieri, A.-B.P.L., Godoi, D.F.,
Moraes, D.A., Coutinho, M.A. Hospital das Clinicas-Univ. Sao Paulo,
Ribeirao Preto, Estado de Sao Paulo, Brazil
The ﬁrst reports of hematopoietic stem cell transplantation
(HSCT) for isolated autoimmune diseases appeared in 1996 and
since then about 700 patients were transplanted. However, very
few patients with vasculites were submitted to HSCT, and all
patients had small or medium size arteritis (1) Fiehn Hensel, High
Dose Chemotherapy with Hematopoietic Stem Cell Transplanta-
tion in Primary Vasculitis, Behcet’s Disease and Sjogren Syn-
drome, in Burt R, Marmont A, eds, Stem Cell Transplantation for
Autoimmune Diseases, Landes Bioscience, in press, 2) Marmont et
al, Bone Marrow Transplantation 31, Suppl 1, S15-16, 2003). We
report here the case of a 41 year old woman with Takayasu’s
arteritis presenting since June 1990 with constitutional symptoms,
polyarthritis, myalgia, dizziness, upper and lower limb claudication
and transient visual impairment. Arteriography showed irregularity
and stenosis of abdmonial aorta, right and left iliac arteries, left
subclavia and carotid arteries. The disease had been treated for 13
years with steroids (PO and IV) and several other immunosupres-
sive agents (methotrexate, cyclophosphamide, chlorambucil and
mycofenolate mophetil) without response. In March 2003, autol-
ogous peripheral blood hematopoietic stem cells were mobilized
with cyclophosphamide (2 g/m2) and G-CSF (10 ug/kg/d), cryo-
preserved and infused (3.9 million/kg) one month later after con-
ditioning with cyclophosphamide (50 mg/kg 4) and rabbit anti-
thymocyte globuline (1,5 mg/kg3). Posttransplant complications
were diarrhea, neutropenic fever and emotional liability, neutro-
phil engraftment occurred at D9 and discharge was on D16.
On D60 the symptoms had improved signiﬁcantly and an an-
gioressonance showed dramatic reduction of brachiocephalic ar-
tery stenosis and carotid arteries irregularities. This rapid improve-
ment suggests that aggressive immunosuppression caused the
observed therapeutic effect in this case but induction of tolerance
and tissue repair mediated by stem cells may operate long term.
This is the ﬁrst case of a large size arteritis treated with HSCT and
illustrate the therapeutic potential of high dose immunosuppres-
sion and cellular therapy in severe vasculitis.
AUTOLOGOUS
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CAN THE STEM CELL MOBILIZATION TECHNIQUE INFLUENCE CD34
CELL COLLECTION EFFICIENCY OF LEUKAPHERESIS PROCEDURES IN
PATIENTS WITH HEMATOLOGIC MALIGNANCIES?
Gidron, A., Verma, A., Doyle, M., Villa, M., Shook, T., Gordon, L.,
Singhal, S., Tallman, M., Williams, S., Winter, J., Mehta, J. North-
western University, Chicago
CD34 cell collection efﬁciency (CE) reﬂects the proportion of
CD34 cells that is harvested during apheresis. Higher CE results
in a bigger stem cell collection per procedure; reducing the number
of procedures required to reach the target. 415 leukaphereses done
on 201 patients (1-11 each; median 2) using Cobe Spectra cell
separators over 26 months were studied to determine CD34 cell
CE. Apheresis was done for leukemia (n  54), lymphoma (n 
130), and plasma cell dyscrasias (n  231). Aphereses done with
pre-apheresis peripheral blood CD34 cell count (PBCD34)
0.02% were excluded to reduce variability and calculation error.
Stem cells were mobilized with growth factor (GF; n  119) or
chemotherapy-GF (n 296). 15 (n 202) or 20 (n 213) L blood
volume was processed. The pre-apheresis WBC count was 1-93 
109/L (median 20), and PBCD34 was 1-1104/mm3 (median 19).
The total number of CD34 cells collected was 4-6531  106
(median 151); corresponding to 0.1-111.4  106 (median 2.3) per
kg. There was strong correlation between PBCD34 and the num-
ber of CD34 cells collected (r2  0.80; P  10100). CE was
7-145% (median 46). On multiple regression analysis, higher
WBC (continuous variable; P  0.0001), higher PBCD34 (contin-
uous variable; P  0.009), and greater blood volume processed
(categoric variable; P  0.02) resulted in lower CE. Age, sex,
weight, diagnosis, year, mobilization technique, Hct, and platelets
did not affect CE. PBCD34 counts were higher (median 22 vs 15;
P 0.036) in patients mobilized with chemotherapy-GF compared
to GF alone despite lower WBC counts (median 16 vs 30; P 
0.0001) because of higher %PBCD34 (median 0.16% vs 0.05%;
P  0.0001). CE with WBC 20 was 7-145% (median 53%)
compared to 10-132% (median 40%) with WBC 20 (P  0.0001),
suggesting that WBC 20 may be optimum for apheresis in terms
of maximizing CE. Since PBCD34 increases early during WBC
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